Inventor · disambiguated record
Liqin Liu
Also filed as: LIU LIQIN
13 granted patents·11 pending applications·71 citations·filing 2001–2025
90Inventor score
Top patents by PatentIndex Score
24 records- 0194US10647768B2Multi-chain polypeptide-containing tri-specific binding moleculesMACROGENICS INC·Filed 2015·Granted May 12, 2020·19 cites·21 claims
- 0291US11421031B2Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereofMACROGENICS INC·Filed 2020·Granted Aug 23, 2022·2 cites·22 claims
- 0389US11459394B2Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereofMACROGENICS INC·Filed 2018·Granted Oct 4, 2022·4 cites·8 claims
- 0488US6841386B2Modulation of primary stem cell differentiation using an insulin-like growth factor binding proteinVIACELL INC·Filed 2001·Granted Jan 11, 2005·29 cites·9 claims
- 0587US11942149B2Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereofMACROGENICS INC·Filed 2022·Granted Mar 26, 2024·1 cites·14 claims
- 0686US10633443B2Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereofMACROGENICS INC·Filed 2015·Granted Apr 28, 2020·3 cites·9 claims
- 0785US2024182559A1MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENSMACROGENICS INC·Filed 2023·Application pending·0 cites
- 0884US11639386B2Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereofMACROGENICS INC·Filed 2020·Granted May 2, 2023·1 cites·10 claims
- 0984US9908938B2Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereofMACROGENICS INC·Filed 2014·Granted Mar 6, 2018·6 cites·27 claims
- 1084US2025313628A1Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereofMACROGENICS INC·Filed 2025·Application pending·0 cites
- 1183US11820818B2Multi-chain polypeptide-containing tri-specific binding moleculesMACROGENICS INC·Filed 2020·Granted Nov 21, 2023·1 cites·16 claims
- 1283US10717778B2Bispecific molecules comprising an HIV-1 envelope targeting armUNIV DUKE·Filed 2015·Granted Jul 21, 2020·3 cites·20 claims
- 1382US12173051B2Bispecific molecules comprising an HIV-1 envelope targeting armUNIV DUKE·Filed 2020·Granted Dec 24, 2024·1 cites·16 claims
- 1481US2023399399A1Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses ThereofMACROGENICS INC·Filed 2023·Application pending·0 cites
- 1579US10730947B2Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereofMACROGENICS INC·Filed 2018·Granted Aug 4, 2020·1 cites·18 claims
- 1677US2023167178A1Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses ThereofMACROGENICS INC·Filed 2022·Application pending·0 cites
- 1771US2024233818A1Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereofMACROGENICS INC·Filed 2024·Application pending·0 cites
- 1862US2025236646A1Truncated varicella-zoster virus envelope glycoprotein geUNIV XIAMEN·Filed 2023·Application pending·0 cites
- 1953US2025051413A1Chimeric molecules comprising il-12 agonist polypeptideASKGENE PHARMA INC·Filed 2022·Application pending·0 cites
- 2049US2022289822A1Novel il-21 prodrugs and methods of use thereofASKGENE PHARMA INC·Filed 2020·Application pending·0 cites
- 2149US2022306714A1Il-2 fusion proteins that preferentially bind il-2ralphaASKGENE PHARMA INC·Filed 2020·Application pending·0 cites
- 2247US2021246194A1Optimized gp41-Binding Molecules and Uses ThereofMACROGENICS INC·Filed 2019·Application pending·0 cites
- 2346US11795226B2Bispecific CD16-binding molecules and their use in the treatment of diseaseMACROGENICS INC·Filed 2018·Granted Oct 24, 2023·0 cites·20 claims
- 2441US2017157251A1Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses ThereofMACROGENICS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Liqin Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →